Inequities in atherosclerotic cardiovascular disease prevention

被引:1
|
作者
Gomez, Sofia E. [1 ]
Dudum, Ramzi [1 ]
Rodriguez, Fatima [2 ]
机构
[1] Stanford Univ, Dept Med, Div Cardiovasc Med, Stanford, CA USA
[2] Stanford Univ, Ctr Acad Med, Div Cardiovasc Med, 453 Quarry Rd, Stanford, CA 94304 USA
关键词
Cardiovascular disease prevention; Inequity; Health disparities; NUTRITION EXAMINATION SURVEYS; AMERICAN HEART ASSOCIATIONS; CARDIAC REHABILITATION; NATIONAL-HEALTH; UNITED-STATES; SOCIAL DETERMINANTS; CLINICAL-TRIALS; SEX-DIFFERENCES; RISK-FACTORS; US ADULTS;
D O I
10.1016/j.pcad.2024.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerotic cardiovascular (CV) disease (ASCVD) prevention encompasses interventions across the lifecourse: from primordial to primary and secondary prevention. Primordial prevention begins in childhood and involves the promotion of ideal CV health (CVH) via optimizing physical activity, body mass index, blood glucose levels, total cholesterol levels, blood pressure, and sleep while minimizing tobacco use. Primary and secondary prevention of ASCVD thereafter centers around mitigating ASCVD risk factors via medical therapy and lifestyle interventions. Disparities in optimal preventive efforts exist among historically marginalized groups in each of these three prongs of ASCVD prevention. Children and adults with a high burden of social determinants of health also face inequity in preventive measures. Inadequate screening, risk factor management and prescription of preventive therapeutics permeate the care of certain groups, especially women, Black, and Hispanic individuals in the United States. Beyond this, individuals belonging to historically marginalized groups also are much more likely to experience other ASCVD risk -enhancing factors, placing them at higher risk for ASCVD over their lifetime. These disparities translate to worse outcomes, with higher rates of ASCVD and CV mortality among these groups. Possible solutions to promoting equity involve community -based youth lifestyle interventions, improved risk -factor screening, and increasing accessibility to healthcare resources and novel preventive diagnostics and therapeutics.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 50 条
  • [31] Prevention of atherosclerotic cardiovascular disease is possible but poorly put into practice
    De Backer, Guy G.
    KARDIOLOGIA POLSKA, 2020, 78 (05) : 383 - 385
  • [32] Atherosclerotic Cardiovascular Disease Primary and Secondary Prevention in Latino Subgroups
    Kaufmann, Jorge
    Marino, Miguel
    Lucas, Jennifer A.
    Rodriguez, Carlos J.
    Boston, Dave
    Giebultowicz, Sophia
    Heintzman, John
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2024, 39 (11) : 2041 - 2050
  • [33] Primary Prevention of Atherosclerotic Cardiovascular Disease: Controversies and Clinical Considerations
    Newsom, Lydia C.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 484 - 493
  • [34] Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease
    Marquis-Gravel, Guillaume
    Stebbins, Amanda
    Wruck, Lisa M.
    Roe, Matthew T.
    Effron, Mark B.
    Hammill, Bradley G.
    Whittle, Jeff
    Vanwormer, Jeffrey J.
    Robertson, Holly R.
    Alikhaani, Jacqueline D.
    Kripalani, Sunil
    Farrehi, Peter M.
    Girotra, Saket
    Benziger, Catherine P.
    Polonsky, Tamar S.
    Merritt, J. Greg
    Gupta, Kamal
    Mccormick, Thomas E.
    Knowlton, Kirk U.
    Jain, Sandeep K.
    Kochar, Ajar
    Rothman, Russell L.
    Harrington, Robert A.
    Hernandez, Adrian F.
    Jones, W. Schuyler
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (04):
  • [35] Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
    Patrono, Carlo
    EUROPEAN HEART JOURNAL, 2024, 45 (27) : 2362 - 2376
  • [36] Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease
    Barry, Arden R.
    Dixon, Dave L.
    PHARMACOTHERAPY, 2021, 41 (12): : 1056 - 1065
  • [37] Sex Disparities in Prevention of Atherosclerotic Cardiovascular Disease Across the Life Course
    Rodriguez, Fatima
    CIRCULATION, 2023, 147 (07) : 523 - 525
  • [38] Clinician-Patient Risk Discussion for Atherosclerotic Cardiovascular Disease Prevention
    Martin, Seth S.
    Sperling, Laurence S.
    Blaha, Michael J.
    Wilson, Peter W. F.
    Gluckman, Ty J.
    Blumenthal, Roger S.
    Stone, Neil J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (13) : 1361 - 1368
  • [40] Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease An Overview of Systematic Reviews
    Karmali, Kunal N.
    Lloyd-Jones, Donald M.
    Berendsen, Mark A.
    Goff, David C., Jr.
    Sanghavi, Darshak M.
    Brown, Nina C.
    Korenovska, Liliya
    Huffman, Mark D.
    JAMA CARDIOLOGY, 2016, 1 (03) : 341 - 349